Siemens and Janssen Collaborate on Companion Diagnostic

Siemens Healthcare Diagnostics (Tarrytown, NY, USA) has entered into a collaboration with Janssen Pharmaceutica NV (Beerse, Belgium) to design, develop, and commercialize a companion diagnostic test associated with an early-stage compound being developed by Janssen. The compound targets autoantibodies directed against the human β1-adrenergic receptor (β1-AR) that could contribute to the development of heart failure.

Under the agreement, the Siemens Clinical Laboratory (SCL) will work with Janssen to design immunoassay-based companion diagnostic tests for use in Janssen's clinical studies. Siemens will develop and validate an in vitro diagnostic test as a companion diagnostic for the Janssen therapeutic product. The Siemens Clinical Laboratory (SCL) is a high-complexity testing laboratory designed to advance personalized medicine.

Heart failure is generally a progressive disease characterized by the heart muscle’s inability to adequately pump oxygenated blood through the body. For most causes of heart failure, there is no known cure.

“Our relationship with Janssen marks an important next step in Siemens’ personalized medicine strategy,” said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. “As a leading clinical diagnostics company, with the tools and technologies to help define the future of patient care, we are looking forward to collaborating with Janssen and extending their position in cardiac therapies.”

Related Links:
Siemens Healthcare Diagnostics
Janssen Pharmaceutica NV